Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. Earlier stage biotechs are trying to turn their platforms into research revenue as they look to non-profit, government, and private funding sources to advance their preclinical therapeutic programs. Whatever the model, worries abound that the financial woes of the next couple of years could blunt hard-earned momentum.
Two words help explain why researchers, clinicians and patients with life-threatening disease hold so much hope for regenerative medicine: Berlin Man.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.
